This Microcap Just Locked Up New IP in a Massive Pharma Market

2025-12-26 10:28:00 ET

In biotechnology, intellectual property wins often act as quiet but powerful catalysts, particularly when they extend a platform into new therapeutic categories or unlock access to large international markets. As competition intensifies and pipelines mature, patent protection remains a key driver of long-term value, especially for companies advancing novel mechanisms with broad clinical applicability.

Shares of Can-Fite BioPharma Ltd. ( NYSE American: CANF ) are surging Friday after the company announced it was granted a new patent in Brazil covering the treatment of sexual dysfunction. The development strengthens the company’s global intellectual-property portfolio and highlights additional potential for its A3 adenosine receptor agonist platform beyond its core oncology and inflammatory disease programs.

The Brazilian Patent Office granted Patent No. BR112015002697-4, titled “Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction.” The patent provides protection in Brazil for the use of Can-Fite’s proprietary A3AR agonists in treating sexual dysfunction, an area of growing demand within one of Latin America’s largest pharmaceutical markets.

Brazil represents a significant opportunity due to its large population and expanding healthcare sector, particularly for therapies addressing chronic and quality-of-life conditions. Can-Fite noted that sexual dysfunction is associated with vascular, inflammatory, and metabolic pathways, areas where the company’s A3 adenosine receptor technology has already demonstrated biological relevance. Preclinical and clinical data generated by the company suggest that activation of the A3 receptor may modulate key signaling mechanisms involved in erectile and sexual function, supporting the therapeutic rationale behind the newly granted patent.

Management characterized the patent grant as further validation of the versatility of the A3AR agonist platform. Chairperson and Chief Scientific Officer Dr. Pnina Fishman stated that the patent could open the door to future partnering or commercialization opportunities in Latin America.

Beyond sexual dysfunction, Can-Fite continues to advance its pipeline across multiple high-value indications. The company’s lead drug candidate, Piclidenoson, has reported topline results from a Phase III psoriasis trial and has commenced a pivotal Phase III study. Its liver cancer candidate, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma, along with additional trials in MASH and pancreatic cancer, and has received Orphan Drug and Fast Track designations from U.S. and European regulators.

Can-Fite also highlighted CF602, its third drug candidate, which has demonstrated efficacy in the treatment of erectile dysfunction, underscoring the relevance of the newly granted patent. Collectively, the company reports experience in more than 1,600 patients across clinical studies to date, with an established safety profile.

Shares of CANF are up 27.6% at $0.23 in Friday morning trading.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

View more of this article on AllPennyStocks.com.

About AllPennyStocks.com Media, Inc.:

Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.

Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.

AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.

Contact:

AllPennyStocks.com Media, Inc.

Email: ads@allpennystocks.com

Phone: (800) 558-4560 Ext: 101